Invex Therapeutics Ltd (ASX:IXC)
Australia · Delayed Price · Currency is AUD 0.1300
+0.0100 (8.33%)
Jan 30, 2026, 4:10 PM AEST
Invex Therapeutics Revenue
In the fiscal year ending June 30, 2025, Invex Therapeutics had annual revenue of 229.08K AUD, down -81.10%. Invex Therapeutics had revenue of 229.08K in the half year ending June 30, 2025, with 1,781.59% growth.
Revenue
229.08K
Revenue Growth
-81.10%
P/S Ratio
42.65
Revenue / Employee
n/a
Employees
n/a
Market Cap
9.77M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2025 | 229.08K | -983.17K | -81.10% |
| Jun 30, 2024 | 1.21M | 753.17K | 164.06% |
| Jun 30, 2023 | 459.09K | 276.83K | 151.90% |
| Jun 30, 2022 | 182.25K | - | - |
| Jun 30, 2021 | - | - | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Chimeric Therapeutics | 12.68M |
| Immuron | 7.29M |
| Tissue Repair | 2.63M |
| Biotron | 1.81M |
| Acrux | 1.19M |
| InhaleRx | 833.90K |
| Patrys | 828.54K |
| AdAlta | 677.01K |